Valeant Pharmaceuticals International’s Debate About Research Are Misleading, Wrong

free biotech news

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

How can we trust Valeant’s calculations about whether it would create value by buying Allergan for $53 billion when Valeant’s presentation of basic facts about the drug industry is self-serving and misleading?

Hey, check out all the research scientist jobs. Post your resume today!

MORE ON THIS TOPIC